Close Menu

siRNA

Alnylam Pharmaceuticals said this week that it and collaborators have developed a novel class of lipid nanoparticles capable of greater target inhibition than the company's existing lipid delivery agents.

By Doug Macron
About a year and a half after its founding, siRNA delivery firm Qualiber has secured a $30,000 low-interest loan from the North Carolina Biotechnology Center to help it with non-scientific startup activities.

Alnylam Pharmaceuticals announced this week that it has added ALN-APC, an siRNA-based treatment for hemophilia, to its formal drug-development pipeline.

The technology is 100 times more potent that the company's current research-only transfection reagent, according to a Life Tech official.

The partnership will specifically include STP601, Sirnaomics' preclinical treatment for ocular neovascularization diseases, in the Greater China and Southeast Asian markets.

The kinase, LMTK3, regulates estrogen receptor α, which is key to patient response to endocrine therapies like tamoxifen. A study of 613 breast cancer samples linked high LMTK3 expression levels to significantly shorter disease-free survival and overall survival.

Pages

A new analysis suggests warming, not the arrival of humans, led to the extinction of the woolly rhinoceros thousands of years ago, the Economist reports.

Chinese health officials uncovered SARS-CoV-2 viral RNA on imported frozen food, but the New York Times reports catching COVID-19 that way would be unlikely.

The UK has ordered 60 million coronavirus vaccine doses from Novavax and 30 million doses from Janssen, according to the Guardian.

In Science this week: machine learning model predicts whether ion channel mutations will cause disease, and more.